Fresh twists and turns in Indian Herceptin biosimilars case
This article was originally published in Scrip
Executive Summary
An Indian Subject Expert Committee (SEC) has recommended certain changes in Biocon's package insert for trastuzumab, the firm's biosimilar version of Roche's Herceptin, seemingly bringing to the fore simmering issues raked up by Roche in court hearings in a strongly contested case between the firms.